Status:
COMPLETED
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV-1 Infection
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
An open-label, 3-period, fixed-sequence study in a panel of 18 HIV-infected patients on MK0518 as part of a stable treatment regimen for HIV.
Eligibility Criteria
Inclusion
- Patient is Human immunodeficiency virus (HIV) positive
- Patient is taking an MK0518 (Raltegravir) containing regimen
- Patient has not had any changes to his/her antiviral regimen in the last 2 weeks
- Patient who is of reproductive potential agrees to use an acceptable method of birth control
- Patients baseline health is stable
Exclusion
- Patient has a history of stroke or chronic seizures.
- Patient has a history of gastric bypass surgery
- Patient is pregnant of breastfeeding
- Patient consumes excessive amounts of caffeinated beverages daily
- Patient has had major surgery, donated blood, or participated in another investigational study in the past 4 weeks
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01000818
Start Date
June 1 2008
End Date
March 1 2009
Last Update
March 21 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.